Clinically reviewed by Dr. Ponlawat Pitsuwan, Physician, Phuket Island Rehab
Quaaludes (methaqualone) are a synthetic sedative-hypnotic drug that was removed from the pharmaceutical market in the 1980s due to widespread abuse, severe physical dependence and fatal overdose risk. Classified as a DEA Schedule I substance in the United States since 1984, methaqualone has no accepted medical use. It remains available on the illicit market, particularly in South Africa and parts of Southeast Asia, and continues to cause addiction and death.
Quaaludes occupy a unique place in drug history. Synthesised in India in 1951, marketed globally as a safe alternative to barbiturates, prescribed to millions for insomnia and anxiety through the 1960s and 1970s, and then banned after it became clear that the drug was neither safe nor non-addictive. At their peak, Quaaludes were the most commonly prescribed sedative in the United States and the sixth most popular recreational drug in the country. The story of methaqualone is a cautionary tale about pharmaceutical marketing, regulatory failure and the speed at which a “safe” medication can become a public health crisis.
“Methaqualone is relevant to our work because we still encounter it,” explains Dr. Ponlawat Pitsuwan, Physician at Phuket Island Rehab. “In Southeast Asia, illicitly manufactured methaqualone tablets, often called Mandrax, still circulate. Patients who present with methaqualone dependence face a withdrawal syndrome that is medically dangerous and requires the same careful management as barbiturate or benzodiazepine withdrawal.”
What Are Quaaludes?
Methaqualone (2-methyl-3-o-tolyl-4(3H)-quinazolinone) is a quinazolinone-class sedative-hypnotic that acts primarily as a positive allosteric modulator of the GABA-A receptor, enhancing the inhibitory effect of gamma-aminobutyric acid on the central nervous system. It also has anticonvulsant, muscle relaxant and local anaesthetic properties. Unlike benzodiazepines, which bind to a specific subunit of the GABA-A receptor, methaqualone binds to a distinct site and produces a qualitatively different form of sedation characterised by a pronounced euphoric “body high,” reduced inhibition and a dissociative state that users describe as a warm, tingling relaxation.
It was marketed under numerous brand names including Quaalude (Rorer), Mandrax (Roussel), Sopor, Parest and Mequin. Standard therapeutic doses ranged from 150 to 300 mg for insomnia. Recreational users typically took 300 to 600 mg, and heavy users consumed 2,000 mg or more per day. The drug was available as tablets, often the iconic Rorer 714 white disc that became a cultural symbol of 1970s excess.
History and Rise of Methaqualone
| Year | Event |
|---|---|
| 1951 | Methaqualone first synthesised by Indra Kishore Kacker and Syed Husain Zaheer in India |
| 1962 | Marketed in Europe and Japan as a safe, non-addictive sedative (Mandrax, Revonal) |
| 1965 | Introduced to the U.S. market as Quaalude by William H. Rorer Inc. |
| 1972 | Became the sixth most popular recreational drug in the U.S.; “Luding out” entered slang |
| 1973 | Reclassified to Schedule II by the DEA due to emerging abuse and overdose data |
| 1984 | Reclassified to Schedule I; all legal U.S. production ceased; no accepted medical use |
| Present | Illicit production continues in India, Southern Africa and parts of Southeast Asia |
Effects and Dangers
At low recreational doses, methaqualone produces relaxation, euphoria, reduced inhibition and increased sociability, effects that made it enormously popular as a “party drug” and an aphrodisiac in the 1970s. At higher doses, the drug causes ataxia (loss of motor coordination), slurred speech, impaired judgement and eventually loss of consciousness. Unlike benzodiazepines, which have a relatively wide therapeutic index, methaqualone has a narrow margin between the dose that produces the desired high and the dose that causes respiratory depression, coma and death.
The risk escalates dramatically when methaqualone is combined with alcohol, which was one of its most common use patterns. Both substances potentiate each other’s GABAergic effects, creating a synergistic CNS depression that frequently proved fatal. There is no specific antidote for methaqualone overdose. Treatment is entirely supportive: airway management, mechanical ventilation and haemodynamic monitoring in an intensive care setting.
Illicitly manufactured methaqualone tablets (Mandrax) have no quality control. The actual methaqualone content varies wildly between tablets, and many contain adulterants including diazepam, diphenhydramine and industrial chemicals. This unpredictability makes every dose a gamble with potentially lethal consequences.
Methaqualone vs Other Sedatives
| Feature | Methaqualone | Benzodiazepines | Barbiturates |
|---|---|---|---|
| Receptor target | GABA-A (distinct binding site) | GABA-A (benzodiazepine site) | GABA-A (barbiturate site) |
| Therapeutic index | Narrow | Wide | Narrow |
| Euphoria | Pronounced | Mild | Moderate to pronounced |
| Overdose antidote | None | Flumazenil | None |
| Withdrawal danger | High (seizures, psychosis) | High (seizures, DTs) | Very high (seizures, death) |
| Current legal status | Schedule I (banned) | Schedule IV (prescription) | Schedule II-IV (restricted) |
Methaqualone Withdrawal and Treatment
Methaqualone dependence develops rapidly with regular use, and withdrawal is medically serious. The withdrawal syndrome resembles barbiturate withdrawal and includes anxiety, insomnia, tremor, nausea, vomiting, tachycardia, hypertension, hallucinations and tonic-clonic seizures. In severe cases, delirium and cardiovascular collapse can occur. Withdrawal must be managed in a medical facility with a cross-tapering protocol using a long-acting benzodiazepine (typically diazepam or phenobarbital) to prevent seizures while the brain readjusts its GABAergic tone.
“Treating methaqualone dependence follows the same principles as treating barbiturate or severe benzodiazepine dependence,” explains Dr. Ponlawat Pitsuwan. “The key is a slow, medically supervised taper with anticonvulsant coverage. Rushing the process risks withdrawal seizures. After stabilisation, the patient transitions into psychotherapy, relapse prevention planning and treatment of any co-occurring psychiatric conditions.”
If you or someone you know is using methaqualone (Mandrax) and wants to stop, do not attempt to quit abruptly. The withdrawal can produce life-threatening seizures. Medical detoxification in a supervised setting is essential for safe cessation.
Frequently Asked Questions
Are Quaaludes still made?
No pharmaceutical company legally manufactures methaqualone anywhere in the world. However, illicit production continues, primarily in clandestine laboratories in India and southern Africa. These illicitly manufactured tablets are sold as Mandrax and vary widely in purity and dosage.
Why were Quaaludes banned?
Quaaludes were banned because the evidence showed that they were highly addictive, commonly abused, frequently involved in fatal overdoses (particularly when combined with alcohol) and had no medical advantage over safer alternatives like benzodiazepines. The DEA reclassified methaqualone to Schedule I in 1984, meaning it has high abuse potential and no accepted medical use.
What do Quaaludes feel like?
Users describe a warm, tingling body sensation, euphoria, deep relaxation, reduced inhibition and a dreamy, dissociative state. At higher doses, motor coordination deteriorates significantly, speech becomes slurred and the user may lose consciousness. The subjective experience was often compared to a combination of alcohol intoxication and muscle relaxation, but with more pronounced euphoria.
Can you overdose on Quaaludes?
Yes. Methaqualone has a narrow therapeutic index, meaning the difference between a recreational dose and a potentially fatal dose is small. Overdose causes respiratory depression, coma and death. There is no antidote; treatment is entirely supportive. The risk is multiplied when methaqualone is taken with alcohol or other CNS depressants.
What is Mandrax?
Mandrax was the brand name for a methaqualone-diphenhydramine combination tablet originally manufactured by Roussel Laboratories. The brand was discontinued, but the name Mandrax persists as street terminology for illicitly manufactured methaqualone tablets, particularly in South Africa, where the drug remains a significant substance abuse problem.
How does methaqualone withdrawal compare to benzodiazepine withdrawal?
Both produce a similar CNS rebound syndrome with anxiety, insomnia, tremor, seizures and potential delirium. Methaqualone withdrawal tends to have a shorter onset (12 to 24 hours after last dose) and a more intense peak but shorter overall duration than long-acting benzodiazepine withdrawal. Both require medical supervision and anticonvulsant coverage for safe management.
Sources
- DEA. “Methaqualone.” Drug Fact Sheet. DEA.gov.
- NCBI Bookshelf. “Sedative, Hypnotic, Anxiolytic Use Disorders.” StatPearls, 2024.
- Inciardi, J.A. “The Rise and Decline of Methaqualone.” Bulletin on Narcotics, 1981.
- Parry, C.D.H. et al. “Methaqualone (Mandrax) Use in South Africa.” South African Medical Journal, 2004.
- Medscape. “Methaqualone: Drug Information.” medscape.com.
- Lerner, A.G. and Gelkopf, M. “Methaqualone Abuse Patterns.” Substance Abuse, 2012.
Quaaludes, methaqualone, Mandrax, Rorer 714, quinazolinone, GABA-A receptor, sedative-hypnotic, Schedule I, DEA, barbiturate, benzodiazepine, flumazenil, phenobarbital, diazepam, CNS depressant, respiratory depression, therapeutic index, diphenhydramine, cross-taper, withdrawal seizure, alcohol interaction, Phuket Island Rehab.